We are committed to developing and increasing access to gene and cell therapies for patients around the world. Our mission 2025: to build a fully integrated global gene and cell therapy company with industry-leading R&D, manufacturing and commercialization capabilities.
Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The management team has extensive leadership experience at leading US and Global gene and cell therapy companies across all functional areas.
Exegenesis Bio has raised over $120 M during the past two years and is now expanding globally with offices in Philadelphia, Boston, China and Singapore.
The company is advancing an early to clinical-stage gene therapy pipeline with three initial focused therapeutic areas: CNS, ophthalmology, and Liver. The company’s vision is to develop and increase access to gene and cell therapies for patients around the world.